Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 7/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662597 | 0.85 | CETP (0.51) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL23095166 | 0.81 | CETP (0.48) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL18896317 | 0.78 | CETP (0.48) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL22849934 | 0.78 | CETP (0.47) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL21116132 | 0.77 | DYRK1A (0.45) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL18862109 | 0.76 | CETP (0.41) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL14478257 | 0.75 | TAAR1 (0.65) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL8179937 | 0.75 | MEP1B (0.51) | TAAR1 | |
| SCHEMBL1416997 | 0.74 | CETP (0.56) | VNN1CETPCHRM2CHRM1CHRM3 | |
| SCHEMBL18922644 | 0.74 | CETP (0.49) | CETPCHRM2CHRM1CHRM3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808447-B2 | Inhibitors of Rho associated protein kinases (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170049760-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049760-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | VNN1 3350/4885CETP 2077/4885CHRM2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.